NCT06770569View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

HRS-3802

HRS-3802

Trial Locations (6)

2065

NOT_YET_RECRUITING

GenesisCare North Shore (Oncology), Saint Leonards

2109

NOT_YET_RECRUITING

Macquarie University Hospital, Sydney

3199

NOT_YET_RECRUITING

Peninsula and South Eastern Haematology & Oncology Group, Frankston

4224

NOT_YET_RECRUITING

John Flynn Private Hospital, Tugun

5000

NOT_YET_RECRUITING

GenesisCare St Andrews, Adelaide

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY